Published in Ann Oncol on January 01, 1993
New strategy for overcoming resistance to chemotherapy of ovarian cancer. Yonago Acta Med (2013) 0.93
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (2000) 5.62
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int (2000) 4.85
Localization of the receptor-binding protein adhesin at the tip of the bacterial pilus. Nature (1987) 4.72
Genes of pyelonephritogenic E. coli required for digalactoside-specific agglutination of human cells. EMBO J (1984) 4.22
Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet (2001) 4.16
Effect of external hip protectors on hip fractures. Lancet (1993) 4.06
The PapG protein is the alpha-D-galactopyranosyl-(1----4)-beta-D-galactopyranose-binding adhesin of uropathogenic Escherichia coli. Proc Natl Acad Sci U S A (1987) 4.05
The Papanicolaou smear histories of 237 patients with cervical cancer. Med J Aust (1992) 3.22
Deletions of chromosomal regions coding for fimbriae and hemolysins occur in vitro and in vivo in various extraintestinal Escherichia coli isolates. Microb Pathog (1990) 3.18
Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol (1993) 3.18
RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer (2006) 3.15
Gene products specifying adhesion of uropathogenic Escherichia coli are minor components of pili. Proc Natl Acad Sci U S A (1986) 2.58
The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol (2013) 2.53
Host-specificity of uropathogenic Escherichia coli depends on differences in binding specificity to Gal alpha 1-4Gal-containing isoreceptors. EMBO J (1990) 2.31
Globoside-specific adhesins of uropathogenic Escherichia coli are encoded by similar trans-complementable gene clusters. J Bacteriol (1985) 2.23
PapD, a periplasmic transport protein in P-pilus biogenesis. J Bacteriol (1989) 2.19
Distant metastases in epithelial ovarian carcinoma. Cancer (1987) 2.07
Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer (2008) 2.03
Successful re-treatment with taxol after major hypersensitivity reactions. J Clin Oncol (1993) 2.00
Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst (2000) 1.99
The role of second-look laparotomy in the long-term survival in ovarian cancer. Ann Oncol (1997) 1.97
[Improved quality of life with ginseng preparations? Positive effects in healthy working people]. Lakartidningen (1995) 1.93
Patients' estimation of overall treatment burden: why not ask the obvious? J Clin Oncol (2002) 1.93
Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol (1991) 1.83
The structure of the human tissue-type plasminogen activator gene: correlation of intron and exon structures to functional and structural domains. Proc Natl Acad Sci U S A (1984) 1.82
Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer (1994) 1.79
Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol (1994) 1.79
Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol (1995) 1.77
North-South twinning in paediatric haemato-oncology: the La Mascota programme, Nicaragua. Lancet (1998) 1.75
Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol (2000) 1.72
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer (2003) 1.70
Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst (1999) 1.70
Informed consent for phase I studies: evaluation of quantity and quality of information provided to patients. Ann Oncol (1995) 1.69
The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer (2003) 1.63
Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol (1994) 1.62
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 1.60
Treatment of childhood Hodgkin's disease with COPP or COPP-ABV (hybrid) without radiotherapy in Nicaragua. Ann Oncol (1997) 1.58
Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.57
Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. J Natl Cancer Inst (2010) 1.55
Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind placebo controlled study. J Rheumatol (1988) 1.53
A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol (2006) 1.51
Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol (1983) 1.49
Myopathy in bone loss of ageing: improvement by treatment with 1 alpha-hydroxycholecalciferol and calcium. Clin Sci (Lond) (1979) 1.49
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.48
Dysplasia epiphysealis hemimelica (Trevor's disease) of the distal radius. Acta Orthop Belg (1998) 1.46
Radical vulvectomy and bilateral inguinal lymphadenectomy through separate groin incisions. Obstet Gynecol (1981) 1.44
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 1.43
From the molecule to the clinic--inhibiting HER2 to treat breast cancer. N Engl J Med (2001) 1.43
Natural killer activity of lymphoid cells isolated from human ascitic ovarian tumors. Int J Cancer (1980) 1.43
Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin. Ann Oncol (1999) 1.42
Prospective randomized study of endovenous radiofrequency obliteration (closure procedure) versus ligation and stripping in a selected patient population (EVOLVeS Study). J Vasc Surg (2003) 1.41
Reprinted article "Prospective randomised study of endovenous radiofrequency obliteration (closure) versus ligation and vein stripping (EVOLVeS): two-year follow-up". Eur J Vasc Endovasc Surg (2011) 1.41
Human papillomavirus deoxyribonucleic acid in adenocarcinoma and adenosquamous carcinoma of the uterine cervix. Obstet Gynecol (1986) 1.40
Genes determining adhesin formation in uropathogenic Escherichia coli. Curr Top Microbiol Immunol (1985) 1.40
The significance of mild squamous atypia on cytology. Aust N Z J Obstet Gynaecol (1995) 1.39
Phase II study of oral menogaril as first line chemotherapy for advanced breast cancer: a National Cancer Institute of Canada Clinical Trials Group study. Ann Oncol (1992) 1.39
[Degenerative lumbar spondylolisthesis and spinal stenosis]. Ugeskr Laeger (1994) 1.39
Changing incidence and residual lifetime risk of common osteoporosis-related fractures. Osteoporos Int (1993) 1.39
Carotid artery revascularisation following neck irradiation: immediate and long-term results. Eur J Vasc Endovasc Surg (2011) 1.38
High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol (2001) 1.38
An easy colorimetric micromethod for routine determination of free fatty acids in plasma. Clin Chim Acta (1973) 1.37
Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.37
Lessons learned from independent central review. Eur J Cancer (2009) 1.30
Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases. Cancer (2000) 1.25
Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer (2004) 1.23
Topoisomerase I inhibitors: topotecan and irenotecan. Cancer Treat Rev (1994) 1.22
Postoperative radiotherapy in Dukes' B and C carcinoma of the rectum and rectosigmoid. A randomized multicenter study. Cancer (1986) 1.22
Local recurrences in giant cell tumour of bone. Long-term follow up of 31 cases. Int Orthop (1996) 1.22
Radial and humeral fractures as predictors of subsequent hip, radial or humeral fractures in women, and their seasonal variation. Osteoporos Int (1993) 1.22
Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2011) 1.21
Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK). Ann Oncol (1998) 1.20
Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. Gynecol Oncol (1990) 1.19
Psychosexual adjustment after vulvar surgery. Obstet Gynecol (1983) 1.19
Rhabdomyosarcoma of the uterine cervix. Sarcoma botryoides. Cancer (1987) 1.19
Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst (2001) 1.18
Additional small acrocentric chromosome: two cases. J Ment Defic Res (1969) 1.17
Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gynecol (1983) 1.16
Epirubicin in extensive small-cell lung cancer: a phase II study in previously untreated patients: a National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol (1990) 1.16
A distinct molecular profile associated with mucinous epithelial ovarian cancer. Br J Cancer (2006) 1.15
Phase II study of amonafide: results of treatment and lessons learned from the study of an investigational agent in previously untreated patients with extensive small-cell lung cancer. J Clin Oncol (1990) 1.13
Current management of epithelial ovarian carcinoma: a review. Semin Surg Oncol (2000) 1.11
Management of regional lymph nodes and their prognostic influence in vulvar cancer. Obstet Gynecol (1983) 1.10
A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol (1994) 1.09
Vitamin D deficiency in obese patients and changes in circulating vitamin D metabolites following jejunoileal bypass. Int J Obes (1982) 1.09
Vitamin D and ischaemic heart disease. Horm Metab Res (1978) 1.09
Phase I trial design: are new methodologies being put into practice? Ann Oncol (1996) 1.08
Vitamin D metabolism in hypoparathyroidism. J Clin Endocrinol Metab (1980) 1.07
Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 1.06
Prospective randomised study of endovenous radiofrequency obliteration (closure) versus ligation and vein stripping (EVOLVeS): two-year follow-up. Eur J Vasc Endovasc Surg (2005) 1.06
Carcinoma of the cervix associated with pregnancy. Obstet Gynecol (1982) 1.06
A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol (1989) 1.06
Regional muscle tension and pain ("fibrositis"). Effect of massage on myoglobin in plasma. Scand J Rehabil Med (1983) 1.06
Natural cytotoxicity on tumour cells of human macrophages obtained from diverse anatomical sites. Clin Exp Immunol (1980) 1.06
Optimal management of endometrial hyperplasia. Best Pract Res Clin Obstet Gynaecol (2001) 1.04